Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PROCEPT BioRobotics (PRCT – Research Report), Cross Country Healthcare (CCRN – Research Report) and CVS Health (CVS – Research Report).
PROCEPT BioRobotics (PRCT)
In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on PROCEPT BioRobotics, with a price target of $72.00. The company’s shares closed last Wednesday at $60.61, close to its 52-week high of $63.26.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of
Currently, the analyst consensus on PROCEPT BioRobotics is a Strong Buy with an average price target of $62.50, a 13.6% upside from current levels. In a report released yesterday, Leerink Partners also reiterated a Buy rating on the stock with a $64.00 price target.
See today’s best-performing stocks on TipRanks >>
Cross Country Healthcare (CCRN)
Truist Financial analyst Tobey Sommer maintained a Hold rating on Cross Country Healthcare today. The company’s shares closed last Wednesday at $17.90.
According to TipRanks.com, Sommer is a 5-star analyst with an average return of
Currently, the analyst consensus on Cross Country Healthcare is a Hold with an average price target of $19.67, which is a 12.0% upside from current levels. In a report released today, Oppenheimer also maintained a Hold rating on the stock.
CVS Health (CVS)
Truist Financial analyst David S Macdonald reiterated a Buy rating on CVS Health today and set a price target of $66.00. The company’s shares closed last Wednesday at $56.31, close to its 52-week low of $54.00.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CVS Health with a $78.12 average price target, which is a 39.5% upside from current levels. In a report released today, RBC Capital also maintained a Buy rating on the stock with a $68.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PRCT:
- Procept BioRobotics sees FY24 revenue $213.5M, consensus $210.18M
- Procept BioRobotics reports Q1 EPS (51c), consensus (56c)
- PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
- Procept BioRobotics announces 12 scientific research presentations
- PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
